Mathes Company’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $396K | Sell |
4,770
-1,775
| -27% | -$147K | 0.15% | 94 |
|
|
2025
Q1 | $531K | Sell |
6,545
-1,100
| -14% | -$89.2K | 0.22% | 81 |
|
|
2024
Q4 | $689K | Sell |
7,645
-1,470
| -16% | -$132K | 0.25% | 71 |
|
|
2024
Q3 | $901K | Sell |
9,115
-325
| -3% | -$32.1K | 0.32% | 65 |
|
|
2024
Q2 | $875K | Sell |
9,440
-1,275
| -12% | -$118K | 0.32% | 65 |
|
|
2024
Q1 | $1.02M | Buy |
10,715
+5,050
| +89% | +$479K | 0.38% | 62 |
|
|
2023
Q4 | $506K | Hold |
5,665
| – | – | 0.21% | 87 |
|
|
2023
Q3 | $414K | Hold |
5,665
| – | – | 0.19% | 91 |
|
|
2023
Q2 | $471K | Buy |
+5,665
| New | +$471K | 0.21% | 92 |
|
|
2022
Q4 | $470K | Sell |
5,665
-1,350
| -19% | -$112K | 0.24% | 87 |
|
|
2022
Q3 | $556K | Sell |
7,015
-6,825
| -49% | -$541K | 0.31% | 76 |
|
|
2022
Q2 | $1.03M | Buy |
13,840
+2,520
| +22% | +$187K | 0.5% | 58 |
|
|
2022
Q1 | $1.02M | Buy |
11,320
+4,750
| +72% | +$427K | 0.39% | 66 |
|
|
2021
Q4 | $736K | Buy |
+6,570
| New | +$736K | 0.25% | 81 |
|
|
2021
Q3 | – | Sell |
-6,495
| Closed | -$879K | – | 125 |
|
|
2021
Q2 | $879K | Buy |
6,495
+1,585
| +32% | +$215K | 0.32% | 75 |
|
|
2021
Q1 | $666K | Buy |
4,910
+500
| +11% | +$67.8K | 0.26% | 82 |
|
|
2020
Q4 | $621K | Sell |
4,410
-205
| -4% | -$28.9K | 0.25% | 84 |
|
|
2020
Q3 | $514K | Buy |
+4,615
| New | +$514K | 0.24% | 83 |
|